{"entity":{"id":"anbogen-therapeutics","kind":"company","name":"Anbogen Therapeutics","aka":["安邦生技"],"tldr":"Anbogen Therapeutics is a Taiwan-based biotechnology company that leads 2 cancer trials in OnCo, testing ABT-101 and ABT-301 in colorectal cancer and non-small-cell lung cancer.","summary":"Anbogen Therapeutics is a precision oncology company in Taipei developing targeted cancer therapies. Its candidates include ABT-101, licensed from Taiwan's National Health Research Institutes, and ABT-301, licensed from Taipei Medical University. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07244705 (phase 1/2, A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advance...) and NCT05532696 (phase 1/2, Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://anbogen.com/"},{"label":"ClinicalTrials.gov: trials led by Anbogen Therapeutics","url":"https://clinicaltrials.gov/search?lead=Anbogen%20Therapeutics%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["abt-301","tislelizumab","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07244705","nct05532696"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://anbogen.com/","founded":2019,"stage":"growth","investors":[],"funding":[]},"route":"/companies/anbogen-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"abt-301","kind":"drug","name":"ABT-301","route":"/drugs/abt-301/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"trial":[{"id":"nct07244705","kind":"trial","name":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","route":"/trials/nct07244705/"},{"id":"nct05532696","kind":"trial","name":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","route":"/trials/nct05532696/"}]}}